The BRAF oncoprotein is involved in transmitting cell growth and proliferation signals from KRAS and NRAS. The BRAF V600E mutation is associated with poorer prognosis and predicts lack of response to anti-EGFR therapies.

BRAF mutational analysis is recommended in clinical guidelines for patients with advanced colorectal cancer as a prognostic marker and factor in determining appropriate therapy. It is a new data item for cases diagnosed 1/1/2021+.

Item #	Length	Source of Standard	Year Implemented	Version Implemented	Year Retired	Version Retired
3940	1	NAACCR	2021	21

0	Normal BRAF negative, BRAF wild type Negative for (somatic) mutations, no alterations, no (somatic) mutations identified, not present, not detected
1	Abnormal (mutated)/detected: BRAF V600E (c.1799T>A) mutation
2	Abnormal (mutated)/detected, but not BRAF V600E (c.1799T>A) mutation
4	Abnormal (mutated), NOS
7	Test ordered, results not in chart
8	Not applicable: Information not collected for this case If this information is required by your standard setter, use of code 8 may result in an edit error.)
9	Not documented in medical record BRAF not assessed or unknown if assessed
Blank	Diagnosis year is prior to 2021

Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.